Education
About Us
Working with TipRanks
Follow Us
Pacira (PCRX)
:PCRX
PCRX Stock Chart & Stats
$21.85
-$0.08(-0.43%)
At close: 4:00 PM EST
$21.85
-$0.08(-0.43%)
Day’s Range― - ―
52-Week Range$16.41 - $27.64
Previous CloseN/A
Volume54.84K
Average Volume (3M)564.80K
Market Cap
$981.78M
Enterprise ValueN/A
Total Cash (Recent Filing)$246.33M
Total Debt (Recent Filing)$425.31M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Feb 19, 2026EPS Estimate
0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.70
Shares Outstanding44,932,720
10 Day Avg. Volume629,963
30 Day Avg. Volume564,800
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.12
Price to Sales (P/S)1.24
P/FCF Ratio4.87
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market PerformanceThe 9% year-over-year increase in Exparel volumes is an encouraging sign that PCRX's efforts via GPOs and NOPAIN are bearing fruit and are returning the product to double-digit growth.
Product SynergyThe approval of Vertex's suzetrigine makes 'opioid-free' a realistic goal for surgeons, creating synergy between the two products and driving adoption.
Regulatory ApprovalThe enactment of the NOPAIN Act removes any barriers to access in key surgical procedures where Exparel is best suited.
Bears Say
Generic CompetitionWith now a path for generics to enter the market, we see a substantial decline in Pacira’s top and bottom lines, and we don’t see any clear path for recovery, which will likely keep investors on the sidelines.
Market PressureThe news is expected to put pressure on PCRX shares, as Qilu seems to be an experienced competitor in the generics and biosimilar space.
Patent ChallengesThe appeal process and litigation of other Exparel patents will likely take years, and ’495 invalidity ruling potentially casts doubt on the strength of the remaining patents.
Pacira Pharmaceuticals News
PCRX FAQ
What was Pacira’s price range in the past 12 months?
Pacira lowest stock price was $16.41 and its highest was $27.64 in the past 12 months.
What is Pacira’s market cap?
Pacira’s market cap is $981.78M.
When is Pacira’s upcoming earnings report date?
Pacira’s upcoming earnings report date is Feb 19, 2026 which is in 78 days.
How were Pacira’s earnings last quarter?
Pacira released its earnings results on Nov 06, 2025. The company reported $0.7 earnings per share for the quarter, beating the consensus estimate of $0.677 by $0.023.
Is Pacira overvalued?
According to Wall Street analysts Pacira’s price is currently Overvalued.
Does Pacira pay dividends?
Pacira does not currently pay dividends.
What is Pacira’s EPS estimate?
Pacira’s EPS estimate is 0.9.
How many shares outstanding does Pacira have?
Pacira has 44,932,720 shares outstanding.
What happened to Pacira’s price movement after its last earnings report?
Pacira reported an EPS of $0.7 in its last earnings report, beating expectations of $0.677. Following the earnings report the stock price went up 4.502%.
Which hedge fund is a major shareholder of Pacira?
Currently, no hedge funds are holding shares in PCRX
Pacira Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
PCRX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 9.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $116.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
19.41%
12-Months-Change
Fundamentals
Return on Equity
2.90%
Trailing 12-Months
Asset Growth
-6.65%
Trailing 12-Months
Company Description
Pacira
Pacira Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative non-opioid pain management solutions. The company operates primarily in the pharmaceutical sector, with a strong emphasis on improving patient outcomes in surgical and non-surgical settings. Pacira's core product, EXPAREL, is a liposomal formulation of bupivacaine designed to provide prolonged local analgesia and reduce the need for opioids post-surgery. The company is dedicated to enhancing the way pain is managed and is committed to advancing its pipeline of products aimed at improving recovery and patient experiences in various surgical procedures.
PCRX Company Deck
PCRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, improved manufacturing efficiencies, and significant pipeline expansion. However, some challenges were noted with Zilretta's slower-than-expected sales growth and discount impacts from new GPO agreements affecting pricing. Elective procedure market growth was also described as sluggish.View all PCRX earnings summariesPCRX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Avadel Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Ownership Overview
2.83% Insiders
25.53% Mutual Funds
20.93% Other Institutional Investors
17.37% Public Companies and
Individual Investors